From the *Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California; †Henry Ford Hospital, Heart and Vascular Institute, Detroit, Michigan; and ‡Division of Gastroenterology, Henry Ford Hospital, Detroit, Michigan.
ASAIO J. 2013 Nov-Dec;59(6):660-1. doi: 10.1097/MAT.0b013e3182a53d00.
Hepatitis C virus (HCV) screening is routine before cardiac transplantation, and virus presence is an exclusion at most centers. Left ventricular assist devices (LVADs) are often used as a bridge to transplantation and cause immune activation. We collected data on 32 consecutive patients undergoing LVAD placement between January 2006 and February 2008 at a single center. Of the 23 potential bridge-to-transplant patients with HCV testing before and after LVAD, seven (30%) turned positive for HCV antibody but did not have true HCV infection on confirmatory testing. Cardiac transplant care providers should be aware of possible false-positive HCV antibody tests in this setting.
丙型肝炎病毒 (HCV) 筛查是心脏移植前的常规检查，大多数中心都将病毒存在作为排除标准。左心室辅助装置 (LVAD) 常被用作移植的桥梁，并引起免疫激活。我们在 2006 年 1 月至 2008 年 2 月期间在一家中心收集了 32 例连续接受 LVAD 植入的患者的数据。在 23 例有 HCV 检测的潜在移植桥接患者中，有 7 例（30%）在 LVAD 前后 HCV 抗体呈阳性，但在确认检测中并未真正感染 HCV。心脏移植护理提供者应该注意到这种情况下可能出现的 HCV 抗体假阳性检测。
